Advertisement

Efficacy of berberine in patients with type 2 diabetes mellitus

  • Jun Yin
    Correspondence
    Corresponding author. Tel.: +1 225 763 2611; fax: +1 225 763 0274.
    Affiliations
    Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China

    Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
    Search for articles by this author
  • Huili Xing
    Affiliations
    Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
    Search for articles by this author
  • Jianping Ye
    Affiliations
    Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
    Search for articles by this author

      Abstract

      Berberine has been shown to regulate glucose and lipid metabolism in vitro and in vivo. This pilot study was to determine the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus patients. In study A, 36 adults with newly diagnosed type 2 diabetes mellitus were randomly assigned to treatment with berberine or metformin (0.5 g 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A1c (from 9.5% ± 0.5% to 7.5% ± 0.4%, P < .01), fasting blood glucose (from 10.6 ± 0.9 mmol/L to 6.9 ± 0.5 mmol/L, P < .01), postprandial blood glucose (from 19.8 ± 1.7 to 11.1 ± 0.9 mmol/L, P < .01), and plasma triglycerides (from 1.13 ± 0.13 to 0.89 ± 0.03 mmol/L, P < .05) were observed in the berberine group. In study B, 48 adults with poorly controlled type 2 diabetes mellitus were treated supplemented with berberine in a 3-month trial. Berberine acted by lowering fasting blood glucose and postprandial blood glucose from 1 week to the end of the trial. Hemoglobin A1c decreased from 8.1% ± 0.2% to 7.3% ± 0.3% (P < .001). Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P < .001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jayaprakasam B.
        • Olson L.K.
        • Schutzki R.E.
        • et al.
        Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas).
        J Agric Food Chem. 2006; 54: 243-248
        • Matsui T.
        • Ueda T.
        • Oki T.
        • et al.
        Alpha-glucosidase inhibitory action of natural acylated anthocyanins. 2. Alpha-glucosidase inhibition by isolated acylated anthocyanins.
        J Agric Food Chem. 2001; 49: 1952-1956
        • Yin J.
        • Hu R.
        • Chen M.
        • et al.
        Effects of berberine on glucose metabolism in vitro.
        Metabolism. 2002; 51: 1439-1443
        • Yin J.
        • Chen M.
        • Tang J.
        • et al.
        Effects of berberine on glucose and lipid metabolism in animal experiment.
        Chin J Diabet. 2004; 12: 215-218
        • Lee Y.S.
        • Kim W.S.
        • Kim K.H.
        • et al.
        Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.
        Diabetes. 2006; 55: 2256-2264
        • Yin J.
        • Gao Z.
        • Liu D.
        • et al.
        Berberine improves glucose metabolism through induction of glycolysis.
        Am J Physiol Endocrinol Metab. 2008; 294: E148-E156
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • et al.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
      1. Ni YX. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 1988;8:711-3, 707

        • DeFronzo R.
        • Goodman A.
        Efficacy of metformin in patients with non–insulin-dependent diabetes mellitus.
        N Engl J Med. 1995; 333: 541-549
        • Ceriello A.
        • Johns D.
        • Widel M.
        • et al.
        Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
        Diabetes Care. 2005; 28: 266-272
        • Tang L.Q.
        • Wei W.
        • Chen L.M.
        • et al.
        Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats.
        J Ethnopharmacol. 2006; 108: 109-115
        • Zhou L.
        • Yang Y.
        • Wang X.
        • et al.
        Berberine stimulates glucose transport through a mechanism distinct from insulin.
        Metabolism. 2007; 56: 405-412
        • Gao C.R.
        • Zhang J.Q.
        • Huang Q.L.
        Experimental study on berberin raised insulin sensitivity in insulin resistance rat models.
        Zhong Xi Yi Jie He Za Zhi. 1997; 17: 162-164
        • Ko B.S.
        • Choi S.B.
        • Park S.K.
        • et al.
        Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma.
        Biol Pharm Bull. 2005; 28: 1431-1437
        • Pan G.Y.
        • Wang G.J.
        • Sun J.G.
        • et al.
        Inhibitory action of berberine on glucose absorption.
        Yao Xue Xue Bao. 2003; 38: 911-914
        • Pan G.Y.
        • Huang Z.J.
        • Wang G.J.
        • et al.
        The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption.
        Planta Med. 2003; 69: 632-636
        • Kong W.
        • Wei J.
        • Abidi P.
        • et al.
        Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
        Nat Med. 2004; 10: 1344-1351
        • Leng S.H.
        • Lu F.E.
        • Xu L.J.
        Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.
        Acta Pharmacol Sin. 2004; 25: 496-502
        • Doggrell S.A.
        Berberine—a novel approach to cholesterol lowering.
        Expert Opin Investig Drugs. 2005; 14: 683-685
        • Abidi P.
        • Zhou Y.
        • Jiang J.D.
        • et al.
        Extracellular signal–regulated kinase–dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2170-2176
        • Brusq J.M.
        • Ancellin N.
        • Grondin P.
        • et al.
        Inhibition of lipid synthesis through activation of AMP-kinase: an additional mechanism for the hypolipidemic effects of Berberine.
        J Lipid Res. 2006; 47: 1281-1288